A Phase 1 Study Of An Intravenously Administered Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer

计划入组 37 人 · 首次发布于 2005 年 9 月 7 日

Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study

计划入组 300 人 · 首次发布于 2025 年 6 月 6 日

Observational Study in Patients with Cyclin-dependent Kinase-like 5 Deficiency Disorder

计划入组 112 人 · 首次发布于 2022 年 5 月 13 日

CDK2 targeting program (Monte Rosa Therapeutics)

SCH-546909

Cyclin dependent kinase 2 degraders(Monte Rosa Therapeutics AG)

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

RIVER 2 RENAL CORP.

United States

Incyclix Bio Raises $11.25 Million to Advance CDK2 Inhibitor INX-315 for Treatment-Resistant Breast and Ovarian Cancers

Integrated Machine Learning and Molecular Dynamics Framework Identifies Novel GSK-3β Inhibitor Candidates for Alzheimer's Disease

Avenzo Therapeutics Initiates CDK4/CDK2 Dual Inhibitor Combination Trial for HR+/HER2- Breast Cancer